Partial response to bevacizumab of an extensive cutaneous angiosarcoma of the face

Br J Dermatol. 2010 Jul;163(1):225-7. doi: 10.1111/j.1365-2133.2010.09803.x. Epub 2010 Apr 12.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged, 80 and over
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Facial Neoplasms / drug therapy*
  • Female
  • Hemangiosarcoma / drug therapy*
  • Humans
  • Treatment Outcome

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab